drugset / Trial / NCT00916292

Safety Study of Topical Human FGF-1 for Wound Healing

NCT00916292 ↗

Phase 1 Unknown 8 enrolled Phage Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to see if FGF-1 is safe when applied topically to the surface of a wound.

Timeline

Start
2012-11
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject FGF-1 141 Unknown 0.3 unknown —
Subject FGF-1 141 Unknown 3 unknown —

Indications